Author

E. Bosman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

D. Wilbie· 1 shared E. Mastrobattista· 1 shared J. J. Molenaar· 1 shared J. Walther· 1 shared O. G. de Jong· 1 shared S. Eising· 1 shared V. Amo-Addae· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

D. Wilbie

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out

D. Wilbie, S. Eising, V. Amo-Addae, J. Walther, E. Bosman, O. G. de Jong, J. J. Molenaar, E. Mastrobattista

This study screens cancer drugs to find those that enhance HDR over NHEJ in CRISPR gene editing, identifying Aurora kinase A inhibitors as promising candidates.

PLOS One · Sep 26, 2025Peer-reviewedPharmacology & Toxicology